Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.
about
Immunotherapy of Ovarian Cancer: The Role of Checkpoint InhibitorsHuman melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease.Bevacizumab plus ipilimumab in patients with metastatic melanoma.Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinomaSignificance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment.Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptorDual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.Effect of Th1/Th2 cytokine administration on proinflammatory SKOV-3 cell activation.Chemokine receptors in epithelial ovarian cancerDeciphering and reversing tumor immune suppression.Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.Overexpression of GOLPH3 protein is associated with worse prognosis in patients with epithelial ovarian cancer.Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression
P2860
Q26799812-B5180B5A-53A0-4202-98D0-BE2E94EBE570Q30274920-4CF3656F-8F4F-4240-A7DE-A80101A89B6DQ34178740-10B73928-4DAA-4DCA-9530-210A4D7C8D57Q35012765-E3CB5D7C-D0E3-46C6-99AD-3104C3FA80CCQ35051622-1E49D768-49EB-42AE-B90C-3D0DCF5BA7FFQ35406476-84AAE1F6-CE91-4A5C-B2D1-EDE2ED20151AQ35954103-CF3C3199-F4D0-437A-9A1B-A1145E32FB20Q36147848-EE168E14-623A-4050-A304-6EA2DC81CD5EQ36588721-600276A1-0A63-467C-AAA0-DA79366BCDDEQ36941194-875BCE0B-9753-43B4-8D47-C542AA980168Q37224568-F0F4EE06-D822-4897-A6DC-BF1BEB1C07ADQ37412635-A624CA18-E4CA-4328-925A-0441852DDB58Q37535454-84354B8E-D4ED-4E0E-91D2-84C525018521Q38124437-F2C4A94D-F98B-4FEF-98D4-23E5F580B459Q39402079-CF3504F3-6FC2-4DA9-B73F-A44355FC1AE8Q39661584-95DB5AF6-FCA6-4656-9C13-832B951997B4Q42695076-CC041A53-9AFA-40EF-9EC4-17782B719E12Q43412012-5A041C4B-BA42-47E4-9CB4-DF966419A1B5Q56889963-9B7F186D-6170-4B47-AF48-BDE77E4E798B
P2860
Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor immune surveillance and ...... tumor rejection or tolerance.
@en
Tumor immune surveillance and ...... tumor rejection or tolerance.
@nl
type
label
Tumor immune surveillance and ...... tumor rejection or tolerance.
@en
Tumor immune surveillance and ...... tumor rejection or tolerance.
@nl
prefLabel
Tumor immune surveillance and ...... tumor rejection or tolerance.
@en
Tumor immune surveillance and ...... tumor rejection or tolerance.
@nl
P2093
P2860
P1476
Tumor immune surveillance and ...... tumor rejection or tolerance.
@en
P2093
George Coukos
Gregory T Motz
Jaikumar Duraiswamy
Lana E Kandalaft
P2860
P2888
P304
P356
10.1007/S10555-011-9289-9
P577
2011-03-01T00:00:00Z